Gene Analysis in Studying Susceptibility to Wilms Tumor

A Genome-Wide Association Study in Wilms Tumor

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01808079

Enrollment

Registered

2013-03-11

Start date

2009-10-31

Completion date

2009-11-30

Last updated

2016-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent Childhood Kidney Neoplasm, Stage III Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage I Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor

Brief summary

This clinical trial studies gene analysis in studying susceptibility to Wilms tumor. Finding genetic markers for Wilms tumor may help identify patients who are at risk of relapse.

Detailed description

PRIMARY OBJECTIVES: I. To use a genome-wide association analysis to identify novel genetic variants that confer susceptibility to Wilms tumor. II. To improve our understanding of the genetic architecture and etiology of Wilms tumor. III. To facilitate the identification of genetic markers that are associated with an increased risk of developing of Wilms tumor and/or those at risk of aggressive disease, relapse, additional tumors and/or cancer in their offspring. OUTLINE: Samples are analyzed for single nucleotide polymorphism (SNP) profiling using real-time polymerase chain reaction (PCR) and multiplex ligation-dependent probe amplification (MLPA).

Interventions

OTHERLaboratory Biomarker Analysis

Correlative studies

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* 3000 samples from the 1958 Birth Cohort (58C) and 3000 from the UK Blood Service control series (NBS)

Design outcomes

Primary

Measure	Time frame	Description
Frequencies between cases and controls at each SNP	Baseline	Compared using the Cochran Armitage trend test (1-df). The data will be analyzed individually for the UK/US study populations and combined using a Mantel-Haenszel analysis adjusting for study group, and related methods which allow for different effects in each population (for confirmed loci, we will compare effects across populations).
Frequency of maternal and paternal allelic transmission for risk alleles	Baseline	Compared using a chi-squared test.
Genetic variation on sub-phenotypes such as age at diagnosis, unilateral or bilateral disease, sex, and ethnicity	Baseline	—
Interactions between genetic variation and treatment success or prognosis	Baseline	—
Interactions between germline genetic variation and tumor phenotypes	Baseline	—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026